-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] A few days ago, Suzhou Baimai Biopharmaceutical .
, L.
announced the completion of a series A financing of more than 50 million yu.
This round of financing was exclusively invested by Linghang New Territori.
The proceeds from this financing will be used to promote the research and development and clinical trials of the company's tumor immunotherapy platform pipeline, as well as the construction of other platform technologies, while further improving the research and development team and expanding the research and development si.
It is understood that since the beginning of this year, pharmaceutical financing has been acti.
Recently, the pharmaceutical industry has added many successful financing cas.
Including Hengyu Biology announced the completion of A+ round of financi.
This round of financing was led by the domestic investment institution Guofang Capital, followed by Haibang Investment, and the old shareholder Chengshu Investment continued to suppo.
The financing amount has not been disclos.
This round of financing will be used for capacity expansion, improvement of technology and compliance systems, and establishment of quality testing kit products and gene therapy-related clinical pharmacy research platfor.
Deeply build a high-standard biosafety industry CXO enterpri.
In addition, Mozhuo Bio also recently announced the completion of the A+ round of financing of nearly 100 million yu.
The funds raised in this round of financing will be mainly used to further expand the company's single-cell product research and development pipeline and vigorously promote the world's unique high-throughput microbial single-cell genomi.
Platform (MobiMicrobe™) research and development and promotion, and continue to promote the research and development, production, commercialization and market development of various products, and strive to accelerate the creation of a diverse and efficient single-cell ecosystem with other industry practitione.
According to statistics, in the first half of 2022, there have been 632 investment and financing events in the medical and health sector nationwide, and the disclosed investment and financing amount is 112 billion yu.
Among them, there were 583 investment and financing events in the primary market, with an investment and financing amount of 61 billion yuan; 30 IPO events, with a fundraising amount of 37 billion yuan; and 19 refinancing events in the secondary market, with a refinancing amount of 14 billion yu.
It can be seen from the data that in the context of the downturn in the general environment, investment and financing in the medical and health field in the first half of 2022 are still active, but the overall trend has slowed do.
Industry analysts believe that financing in the medical and health sector has slowed down compared with the previous two years, which is an obvious tre.
The root cause is that the changes in the macro environment in the past two years have led to intensified fluctuations in the capital market, and factors such as sector rotation and biopharmaceutical companies are no longer at the forefro.
But on the whole, the investment and financing of innovative drugs, medical devices and other tracks are still heating up, attracting an influx of capit.
According to data, innovative drugs and medical devices are still favored by capital, with over 300 investment and financing events in the first half of the ye.
Among them, there are 161 cases in the field of innovative drugs and 150 cases in medical devic.
In general, investment and financing data can predict the performance of the secondary mark.
From the current point of view, although the investment and financing trend in the medical and health field has begun to slow down, the investment opportunities in the medical and health field are still favored by the indust.
Among them, especially new cell therapy, gene therapy, tumor therapy, genetic testing and other fields are expected to still attract the attention of innovative drug compani.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
, L.
announced the completion of a series A financing of more than 50 million yu.
This round of financing was exclusively invested by Linghang New Territori.
The proceeds from this financing will be used to promote the research and development and clinical trials of the company's tumor immunotherapy platform pipeline, as well as the construction of other platform technologies, while further improving the research and development team and expanding the research and development si.
It is understood that since the beginning of this year, pharmaceutical financing has been acti.
Recently, the pharmaceutical industry has added many successful financing cas.
Including Hengyu Biology announced the completion of A+ round of financi.
This round of financing was led by the domestic investment institution Guofang Capital, followed by Haibang Investment, and the old shareholder Chengshu Investment continued to suppo.
The financing amount has not been disclos.
This round of financing will be used for capacity expansion, improvement of technology and compliance systems, and establishment of quality testing kit products and gene therapy-related clinical pharmacy research platfor.
Deeply build a high-standard biosafety industry CXO enterpri.
In addition, Mozhuo Bio also recently announced the completion of the A+ round of financing of nearly 100 million yu.
The funds raised in this round of financing will be mainly used to further expand the company's single-cell product research and development pipeline and vigorously promote the world's unique high-throughput microbial single-cell genomi.
Platform (MobiMicrobe™) research and development and promotion, and continue to promote the research and development, production, commercialization and market development of various products, and strive to accelerate the creation of a diverse and efficient single-cell ecosystem with other industry practitione.
According to statistics, in the first half of 2022, there have been 632 investment and financing events in the medical and health sector nationwide, and the disclosed investment and financing amount is 112 billion yu.
Among them, there were 583 investment and financing events in the primary market, with an investment and financing amount of 61 billion yuan; 30 IPO events, with a fundraising amount of 37 billion yuan; and 19 refinancing events in the secondary market, with a refinancing amount of 14 billion yu.
It can be seen from the data that in the context of the downturn in the general environment, investment and financing in the medical and health field in the first half of 2022 are still active, but the overall trend has slowed do.
Industry analysts believe that financing in the medical and health sector has slowed down compared with the previous two years, which is an obvious tre.
The root cause is that the changes in the macro environment in the past two years have led to intensified fluctuations in the capital market, and factors such as sector rotation and biopharmaceutical companies are no longer at the forefro.
But on the whole, the investment and financing of innovative drugs, medical devices and other tracks are still heating up, attracting an influx of capit.
According to data, innovative drugs and medical devices are still favored by capital, with over 300 investment and financing events in the first half of the ye.
Among them, there are 161 cases in the field of innovative drugs and 150 cases in medical devic.
In general, investment and financing data can predict the performance of the secondary mark.
From the current point of view, although the investment and financing trend in the medical and health field has begun to slow down, the investment opportunities in the medical and health field are still favored by the indust.
Among them, especially new cell therapy, gene therapy, tumor therapy, genetic testing and other fields are expected to still attract the attention of innovative drug compani.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
